Comments
Emcure Pharmaceuticals Ltd made a robust entry into the stock markets, surpassing expectations with significant listing gains at ₹1,325 per share. This translates to a considerable 31.45% gain over its issue price of ₹1,008. According to Prashanth Tapse, Senior VP (Research) at Mehta Equities Ltd, the IPO saw enthusiastic participation from diverse investor segments, buoyed by attractive valuations and Emcure’s prominent position in India’s gynaecology and HIV antiviral therapeutic markets.
- Also read: IPO screener: Emcure Pharma listing today
Tapse highlighted the strong demand from investors as a testament to Emcure’s strategic focus on high-growth therapeutic segments, its innovative product portfolio, successful global expansions, and robust R&D capabilities.
Considering Emcure’s promising long-term prospects, Tapse recommends investors who secured allocations adopt a “HOLD” strategy, emphasising the company’s potential for sustained growth.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.